Hyderabad, Sep 18 (Reporter) Lupin, a global pharmaceutical major, on Wednesday announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited (Takeda), to commercialize Vonoprazan tablets, a Novel Gastrointestinal Drug in India. The drug will be marketed under the brand name Lupin’s Lupivon® and will be available in two strengths - 10 mg and 20 mg, the Mumbai-based pharma company said in a release. Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India. "We are very pleased to commercialize Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients,” said, Rajeev Sibal, President India Region Formulations, Lupin. Acid Peptic Disorder (APD) which includes Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), is a highly prevalent disorder in India. While prevalence of GERD ranges from 5% to 28.5%, PUD has prevalence in the range of Rs 8%. Risk factors for GERD include old age, high body mass index (BMI), non-vegetarian diet, tea/coffee intake, smoking and alcohol consumption. In India, Vonoprazan is approved by the DCGI for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment...////...